Literature DB >> 8988109

Clinical implications of lamivudine resistance by HBV.

S W Schalm1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 8988109     DOI： 10.1016/S0140-6736(05)62154-X

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  4 in total

1.  Combination therapy for hepatitis B.

Authors:  A M Di Bisceglie
Journal:  Gut       Date:  2002-04       Impact factor: 23.059

Review 2.  Treatment of chronic hepatitis B: new antiviral therapies.

Authors:  F Yao; R G Gish
Journal:  Curr Gastroenterol Rep       Date:  1999 Feb-Mar

3.  Liver transplantation in Asian patients with chronic hepatitis B using lamivudine prophylaxis.

Authors:  C M Lo; S T Cheung; C L Lai; C L Liu; I O Ng; M F Yuen; S T Fan; J Wong
Journal:  Ann Surg       Date:  2001-02       Impact factor: 12.969

4.  Phase IIb trial of in vivo electroporation mediated dual-plasmid hepatitis B virus DNA vaccine in chronic hepatitis B patients under lamivudine therapy.

Authors:  Fu-Qiang Yang; Gui-Rong Rao; Gui-Qiang Wang; Yue-Qi Li; Yao Xie; Zhan-Qing Zhang; Cun-Liang Deng; Qing Mao; Jun Li; Wei Zhao; Mao-Rong Wang; Tao Han; Shi-Jun Chen; Chen Pan; De-Ming Tan; Jia Shang; Ming-Xiang Zhang; Yue-Xin Zhang; Ji-Ming Yang; Guang-Ming Chen
Journal:  World J Gastroenterol       Date:  2017-01-14       Impact factor: 5.742
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.